Oncology continues to drive M&A and dealmaking activity

oncology_cancer_large

An analysis of how - and why - oncology remains the hottest area for big-money deals in pharma.

As always, last month's American Society of Clinical Oncology (ASCO) meeting captured a lot of attention from companies and investors, with important new data being presented on Sanofi’s (Euronext: SAN) antibody drug conjugate, Sarclisa (isatuximab) in multiple myeloma, Astellas Pharma (TYO: 4503) Phase III EV-301 trial data with enfortumab vedotin in pre-treated patients with advanced or metastatic urothelial cancer, as well as data from newcomers including I-Mab (Nasdaq: IMAB) with its new CD73 antibody uliledlimab in combination with Roche’s (ROG:SIX) Tecentriq in patients with advanced cancer, and Adicet Bio's (Nasdaq: ACET) off the shelf gamma-delta T-cell therapy ADI-001, in lymphoma.

So why is there such continued interest and investment in oncology?

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical